A Phase 2 trial of a gene therapy for geographic atrophy secondary to dry age-related macular degeneration has been stopped for lack of efficacy, Syncona Ltd, the UK developer, announced on 11 September. This followed a recommendation by the trial’s independent data monitoring committee which concluded that the overall benefit/risk assessment of the therapy didn’t support continuation.
